Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$8.82 - $11.12 $66,670 - $84,056
7,559 Added 50.26%
22,599 $251,000
Q4 2023

Feb 14, 2024

BUY
$6.48 - $11.61 $97,459 - $174,614
15,040 New
15,040 $168,000
Q2 2023

Aug 11, 2023

SELL
$7.27 - $9.82 $1.09 Million - $1.47 Million
-149,891 Reduced 92.92%
11,429 $100,000
Q1 2023

May 16, 2023

BUY
$7.38 - $10.35 $396,357 - $555,867
53,707 Added 49.91%
161,320 $1.34 Million
Q4 2022

Feb 14, 2023

BUY
$7.63 - $10.22 $821,087 - $1.1 Million
107,613 New
107,613 $1.03 Million
Q2 2022

Aug 15, 2022

SELL
$5.17 - $6.33 $438,876 - $537,347
-84,889 Reduced 63.37%
49,075 $277,000
Q1 2022

May 16, 2022

SELL
$4.29 - $6.08 $587 - $832
-137 Reduced 0.1%
133,964 $750,000
Q4 2021

Feb 14, 2022

BUY
$3.89 - $10.01 $416,848 - $1.07 Million
107,159 Added 397.74%
134,101 $590,000
Q3 2021

Nov 15, 2021

BUY
$6.51 - $9.62 $81,661 - $120,673
12,544 Added 87.12%
26,942 $254,000
Q2 2021

Aug 11, 2021

BUY
$5.96 - $7.85 $85,812 - $113,024
14,398 New
14,398 $105,000
Q1 2021

May 17, 2021

SELL
$6.21 - $8.68 $70,595 - $98,674
-11,368 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$5.99 - $8.55 $128,737 - $183,756
-21,492 Reduced 65.4%
11,368 $85,000
Q3 2020

Nov 16, 2020

SELL
$5.19 - $10.17 $654,396 - $1.28 Million
-126,088 Reduced 79.33%
32,860 $199,000
Q2 2020

Aug 14, 2020

BUY
$5.43 - $9.39 $382,434 - $661,337
70,430 Added 79.57%
158,948 $1.33 Million
Q1 2020

May 15, 2020

BUY
$4.89 - $8.1 $155,218 - $257,110
31,742 Added 55.91%
88,518 $526,000
Q4 2019

Feb 14, 2020

BUY
$4.25 - $6.49 $147,628 - $225,436
34,736 Added 157.6%
56,776 $368,000
Q3 2019

Nov 14, 2019

BUY
$3.85 - $4.95 $84,854 - $109,098
22,040 New
22,040 $106,000
Q2 2018

Aug 14, 2018

SELL
$10.05 - $14.33 $569,905 - $812,611
-56,707 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$8.26 - $12.1 $468,399 - $686,154
56,707 New
56,707 $686,000

Others Institutions Holding FENC

About FENNEC PHARMACEUTICALS INC.


  • Ticker FENC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,067,300
  • Market Cap $130M
  • Description
  • Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...
More about FENC
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.